Company Description
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States.
The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.
Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure.
It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy.
It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy.
Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 1997 |
| IPO Date | Apr 29, 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 498 |
| CEO | Robert Blum |
Contact Details
Address: 350 Oyster Point Boulevard South San Francisco, California 94080 United States | |
| Phone | 650 624 3000 |
| Website | cytokinetics.com |
Stock Details
| Ticker Symbol | CYTK |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001061983 |
| CUSIP Number | 23282W605 |
| ISIN Number | US23282W6057 |
| Employer ID | 94-3291317 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robert I. Blum | Chief Executive Officer, President and Director |
| Dr. Fady Ibraham Malik FACC, M.D., Ph.D. | Executive Vice President of Research and Development |
| Andrew M. Callos | Executive Vice President and Chief Commercial Officer |
| Dr. James A. Spudich Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Sung H. Lee | Executive Vice President, Principal Financial and Accounting Officer and Chief Financial Officer |
| Jeff Lotz | Vice President of Sales and Operations |
| Matt Yang | Vice President of Corporate Finance and Financial Planning and Analysis |
| Steven M. Cook J.D. | Senior Vice President of Global Supply Chain Operations and Technical Operations |
| Kari K. Loeser J.D. | Vice President and Chief Compliance Officer |
| Scott R. Jordan | Senior Vice President of Global Marketing and Commercial Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 14, 2025 | 144 | Filing |
| Mar 13, 2025 | 144 | Filing |
| Mar 10, 2025 | 8-K | Current Report |
| Mar 5, 2025 | 144 | Filing |
| Mar 4, 2025 | 144 | Filing |
| Feb 27, 2025 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 12, 2025 | SCHEDULE 13G/A | Filing |
| Feb 11, 2025 | 8-K | Current Report |